Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 13Unknown 7Available 4Recruiting 2No longer available 2Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Cyclophosphamide 3naxitamab 2fludarabine phosphate 2fludarabine 2dinutuximab 2Topotecan 2Granulocyte-Macrophage Colony-Stimulating Factor 2Colony-Stimulating Factors 2sargramostim 1iberdomide 1eliglustat 1Vorinostat 1Thiotepa 1Tacrolimus 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Isotretinoin 1Cyclosporine 1Busulfan 1Biopsy 1Antilymphocyte Serum 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neuroblastoma × 3-Iodobenzylguanidine × Clear all
NCT07261241 2025-12-03

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

New Approaches to Neuroblastoma Therapy Consortium

Phase 2 Not yet recruiting
118 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡